This preprint is under consideration at BMC Research Notes. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research note
Shotaro Nakanishi
University of the Ryukyus: Ryukyu Daigaku
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0117-9490
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objective: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.
Results: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥8 (p = 0.004), an extent of disease value (EOD) of ≥2 (p = 0.004), and a 3-month PSA level >1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. For OS, a 3-month PSA level >1% of the pretreatment level was an independent predictor of time to CRPC (p = 0.004).
Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level >1% of the pretreatment level correlated with poor a prognosis.
Keywords
mHSPC, time to CRPC, prostate cancer, 3-month %PSA
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
- FigureS1.pptx
Kaplan-Meier curve showing the time to CRPC (median: 15 months).
- FigureS2.pptx
Kaplan-Meier curve showing the overall survival (median: 92 months).
- FigureS3.pptx
Comparison of Kaplan-Meier curves between the PSA ≥1% group and the PSA <1% group. The PSA ≥1% group shows a significantly shorter time to CRPC than the PSA <1% group (p = 0.0027).
- SupplementaryTable12021.1.12.docx
Univariate analysis of potential baseline covariates with the time to CRPC.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Mar, 2021
No community comments so far
Reviewer #1 agreed
On 27 Mar, 2021
Reviewers invited
Invitations sent on 26 Feb, 2021
Editor assigned
On 18 Feb, 2021
Submission checks complete
On 18 Feb, 2021
Editor invited
On 18 Feb, 2021
First submitted
On 11 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at BMC Research Notes. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research note
Shotaro Nakanishi
University of the Ryukyus: Ryukyu Daigaku
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0117-9490
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Mar, 2021
No community comments so far
Reviewer #1 agreed
On 27 Mar, 2021
Reviewers invited
Invitations sent on 26 Feb, 2021
Editor assigned
On 18 Feb, 2021
Submission checks complete
On 18 Feb, 2021
Editor invited
On 18 Feb, 2021
First submitted
On 11 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objective: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.
Results: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥8 (p = 0.004), an extent of disease value (EOD) of ≥2 (p = 0.004), and a 3-month PSA level >1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. For OS, a 3-month PSA level >1% of the pretreatment level was an independent predictor of time to CRPC (p = 0.004).
Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level >1% of the pretreatment level correlated with poor a prognosis.
Figure 1
Loading...